TrialEuropean journal of nuclear medicine and molecular imaging2019

Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.

Sabina Dizdarevic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.